Hikma Ventures is the corporate venture arm of Hikma Pharmaceuticals and was established in 2015. It invests in healthcare innovation with a focus on digital health, diagnostics, and technologies that extend beyond traditional pharmaceutical products. Its model combines venture investment with strategic support through the broader Hikma commercial and regulatory platform.

The fund is especially interested in solutions that improve the patient journey, including remote monitoring, digital therapeutics, and AI-enabled diagnostics. In brain and mental health, it has shown interest in data-driven platforms that make treatment response more measurable and clinically actionable. Hikma’s main differentiator is not just capital, but its ability to help portfolio companies navigate market access and commercialization across multiple healthcare systems.

Hikma Ventures has an international footprint, with strategic relevance across the Middle East, North Africa, Europe, and the United States. For neurotech, it is most relevant to digital neurology, computational psychiatry, and monitoring platforms rather than core implant or wet-lab therapeutics. It can be especially attractive for companies seeking strategic entry into MENA-linked healthcare markets.